Clinical trials: Normal Physiology
Diabetic Kidney Disease
Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function
The primary objective of this study is to evaluate the pharmacokinetics (PK) of selonsertib in participants with impaired hepatic function relative to matched, healthy controls.
- Trial name
- NCT02509624
- Testing
- Selonsertib
- Where
- 5 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Renal Impairment
Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function
An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HM15912 in Subjects with Renal Impairment and Matched Control Subjects with Normal Renal Function
- Trial name
- NCT05711381
- Testing
- HM15912
- Where
- 4 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
COVID-19
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with moderate hepatic impairment and subjects without hepatic impairment, matched for age, body weight and, to the extent…
- Trial name
- NCT06568861
- Testing
- ALG-097558
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
Renal Insufficiency
A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney Problems
This study is open to people with and without kidney problems. People can join the study if they are 18 years or older and have a body mass index (BMI) between 18.5 and 35 kg/m2.
- Trial name
- NCT05718843
- Testing
- BI 425809
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Muscular Atrophy, Spinal
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function
This is a multi-center, open-label, non-randomized, parallel-group, 2-part study to evaluate the effect of hepatic impairment on the PK and safety and tolerability of a single oral dose of risdiplam compared to matched healthy…
- Trial name
- NCT03920865
- Testing
- Risdiplam
- Where
- 3 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Pneumonia
A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
This study will evaluate what effect renal dysfunction has on a drug that has an intravenous (CP-70,429) and an oral form (PF-03709270).
- Trial name
- NCT00759564
- Testing
- CP-70,429 and PF-03709270
- Where
- 2 sites in United States, Belgium
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hearing Loss, Sensorineural, Hearing Loss, Conductive
Wide Frequency Band Test of Hearing in Veterans
The accurate assessment of auditory status is critical for planning treatment for Veterans with hearing loss to include medical and audiological management.
- Conditions
- Hearing Loss, Sensorineural, Hearing Loss, Conductive, Hearing Loss, Mixed Conductive-Sensorineural, Otosclerosis
- Trial name
- CWTBAFV (NCT02019888)
- Where
- 2 sites in United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Renal Impairment
A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment
The purpose of the study is to compare the pharmacokinetics, pharmacodynamics, and tolerability of betrixaban in patients with mild, moderate, and severe renal impairment to healthy volunteers.
- Trial name
- NCT00999336
- Testing
- Betrixaban
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Normal Physiology
Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI
Background: Dopamine (DA) is a chemical signal in the brain linked to learning, memory, and habits. Stimulant drugs like methylphenidate can increase DA in the brain. Researchers want to measure DA with and without this drug.
- Trial name
- NCT03326245
- Testing
- Methylphenidate Pill, Intravenous methylphenidate
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
End-Stage Renal Disease (ESRD)
A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)
The primary objective of the study is to evaluate the pharmacokinetics (PK) of avacopan and metabolite (M1) after a single dose of avacopan in participants with normal renal function and participants with ESRD requiring…
- Trial name
- NCT06468826
- Testing
- Avacopan
- Where
- 2 sites in United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy
Pregabalin and Colonic Function
This study is being done to evaluate the effects of pregabalin, a drug approved for anticonvulsive therapy and for neuropathic pain, on colonic and sensory functions in healthy individuals.
- Trial name
- NCT01094808
- Testing
- Pregabalin, Bowel preparation
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Kidney Diseases, Kidney Injury
Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring
The goal of this clinical trial was to compare transdermal glomerular filtration rate (tGFR) to plasma-derived indexed GFR (nGFR) using MB-102 (relmapirazin) as the fluorescent compound.
- Conditions
- Kidney Diseases, Kidney Injury, Kidney Failure
- Trial name
- NCT05777174
- Testing
- MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
- Where
- 5 sites in United States
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- MediBeacon
Hepatic Impairment
A Hepatic Impairment Study for PF-04965842.
This is a Phase 1 non randomized, open label, single dose, parallel cohort study to investigate the effect of hepatic impairment on the PK, safety and tolerability of PF 04965842.
- Trial name
- NCT03626415
- Testing
- PF-04965842
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Congestive Heart Failure
Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
In congestive heart failure, cardiac output is low, blood pressure is high, and the body becomes congested with fluid. In normal people, when there is high blood pressure, the heart muscle cells secrete a hormone that excretes…
- Trial name
- PPG1 (NCT00387621)
- Testing
- Nesiritide, Saline
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Horng Chen
Glioma
Sedatives' Effects on Neurological Function in Patients With Eloquent Area Glioma
Sedation in the operating room, the Post Anesthesia Care Unit and the Intensive Care Unit is common and often necessary for patients with intracranial brain tumor.
- Trial name
- NCT02439164
- Testing
- Midazolam
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Healthy Study Participants, Impaired Hepatic Function
A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function
The purpose of the study is to evaluate the plasma pharmacokinetic (PK), safety and tolerability of padsevonil (PSL) in hepatically impaired and non-hepatically impaired study participants.
- Trial name
- NCT04136444
- Testing
- Padsevonil
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
Moderate Hepatic Impairment, Normal Hepatic Function
A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
The purpose of this study is to determine the effect of hepatic impairment on rivipansel PK and safety.
- Trial name
- NCT02871570
- Testing
- Rivipansel
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlycoMimetics Incorporated
Renal Impairment
A Renal Impairment Study for PF-06651600
This is a Phase 1 non-randomized, open-label, parallel cohort study of PF-06651600 in subjects with severe renal impairment and subjects without renal impairment (Part 1) and in subjects with mild and moderate renal impairment…
- Trial name
- NCT04037865
- Testing
- PF-06651600
- Where
- 3 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteer, Renal Impairment
Renal Impairment Study of PF-06700841
The purpose of this study is to characterize the effect of kidney impairment on the blood concentrations of PF-06700841 and its major metabolite.
- Trial name
- NCT04260464
- Testing
- PF-06700841
- Where
- 3 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatic Impairment
GT-032 Belapectin Hepatic Impairment
This study will assess the pharmacokinetics of belapectin in subjects with mild, moderate, or severe hepatic impairment according to 3 different Child-Pugh categories: mild, moderate, or severe impairment, compared to matched…
- Trial name
- NCT04332432
- Testing
- belapectin
- Where
- 4 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Galectin Therapeutics Inc.